BC
IMVT icon

Boxer Capital’s Immunovant IMVT Stock Holding History

Boxer Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-825,000
Closed -$23.5M – 20
2024
Q3 		$23.5M Hold
825,000
– – 1.15% 25
2024
Q2 		$21.8M Hold
825,000
– – 1.15% 26
2024
Q1 		$26.7M Sell
825,000
-175,000
-18% -$6.38M 1.32% 22
2023
Q4 		$42.1M Buy
1,000,000
+250,000
+33% +$9.2M 2.1% 17
2023
Q3 		$28.8M Buy
+750,000
New +$17M 1.53% 23
2021
Q3 		– Sell
-1,000,000
Closed -$10.6M – 95
2021
Q2 		$10.6M Hold
1,000,000
– – 0.37% 64
2021
Q1 		$16M Buy
+1,000,000
New +$26.4M 0.54% 50

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital's IMVT Position: Q4 2024 in Review

Boxer Capital sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 825,000 shares — an estimated $23.5M sold.

Boxer Capital first reported a position in IMVT in Q1 2021 and held it in 7 quarters. The position peaked at $42.1M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Boxer Capital reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 825,000 Immunovant shares in Q4 2024, an estimated $23.5M.
  • Boxer Capital first reported a position in Immunovant in Q1 2021 and held it in 7 quarters.
  • Boxer Capital's Immunovant position peaked at $42.1M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.